Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: The aim of this study was to analyze the pattern of failure in patients who have undergone surgical resection for cervical esophageal squamous cell carcinoma.
Study Design: Case series with chart review.
Setting: University hospital.
Subjects And Methods: Sixty-two patients who had undergone surgical resection of cervical esophageal squamous cell carcinoma from January 2001 through April 2012. Sites of failure were documented.
Results: Twenty-nine patients had developed treatment failure. Of the 29 patients, 14, 13, and 14 had developed local failure, regional failure, and distant metastasis, respectively. Of the 13 regional failures, the images of 2 patients were lost. The other 11 regional failures included left lateral nodal disease at level II (n = 2), level III (n = 4), and level IV (n = 7); right lateral nodal disease at level II (n = 2), level III (n = 3), and level IV (n = 3); and level VI (n = 4). The overall 2-year local failure-free survival rate and regional failure-free survival rates were 79.6% and 58.6% (P = .04) for patients with stage II disease and 79.6% and 59.6% (P = .054) for patients with stage III disease, respectively.
Conclusions: The pattern of failure of cervical esophageal squamous cell carcinoma is characterized by early locoregional failure, especially in patients with stage III disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0194599814531915 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
McKeown Esophagectomy for Esophageal Cancer Following Pancreaticoduodenectomy Using a Mesenteric Approach for Pancreatic Cancer: A Case Report.
Surg Case Rep
September 2025
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Toyama, Japan.
Introduction: There are no reports of patients undergoing McKeown esophagectomy for esophageal cancer after undergoing pancreaticoduodenectomy for pancreatic cancer. We report the case of a patient who underwent subtotal esophagectomy and colon reconstruction after pancreaticoduodenectomy using the mesenteric approach.
Case Presentation: A 71-year-old male was diagnosed with advanced esophageal cancer.
Endoscopic mucoplasty as a novel approach for cervical esophageal web.
Endoscopy
December 2025
Digestive Disease Center, Showa Medical University Koto Toyosu Hospital, Tokyo, Japan.
Prognostic significance of estimated radiation dose to immune cells in cancer patients undergoing thoracic irradiation: A meta-analysis.
Radiother Oncol
September 2025
College of Medicine, Chang Gung University, Taoyuan, Taiwan; Department of Radiation Oncology, Proton and Radiation Therapy Center, Chang Gung Memorial Hospital-Linkou Medical Center, Taiwan. Electronic address:
Background And Purpose: Emerging evidence suggests that excessive radiation dose to immune cells may impair host immunity and negatively affect cancer prognosis. However, the prognostic impact of the estimated radiation dose to immune cells across different cancer types and treatment modalities remains inconclusive. This meta-analysis aimed to systematically evaluate the association between estimated radiation dose to immune cells and survival outcomes in patients with lung and esophageal cancers undergoing radiotherapy.
View Article and Find Full Text PDFQuality indicator survey of clinical practice guidelines for esophagogastric junction cancer 2023.
Dis Esophagus
October 2025
Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
Clinical practice guidelines for esophagogastric junction cancer (EGJ GLs) were published in 2023. In order to evaluate how EGJ GLs have been adopted into clinical practice worldwide and to identify any outstanding clinical questions to be addressed in the next edition, this survey was conducted. An electronic questionnaire was developed.
View Article and Find Full Text PDFComparison of the Anticancer Effects of a Complementary Peptide for Dickkopf WNT Signaling Pathway Inhibitor 3 (DKK3) With Conventional Anticancer Drugs in the Treatment of Oral Squamous Cell Carcinoma: A Pilot Study.
Cureus
September 2025
Department of Oral Pathology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, JPN.
Introduction Oral squamous cell carcinoma (OSCC), which is the most common cancer type in head and neck cancers, remains a serious health problem because of its high mortality. Treatment of OSCC is mainly performed with a combination of surgery and anticancer agents. However, despite the recent development of anticancer agents, the clinical outcome of OSCC has yet to be improved.
View Article and Find Full Text PDF